Duvall Diantha 4
4 · GENOCEA BIOSCIENCES, INC. · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Duvall Diantha
CHIEF FINANCIAL OFFICER
Transactions
- Award
Common Stock
2022-03-15+37,500→ 95,611 total - Sale
Common Stock
2022-03-16$1.10/sh−2,873$3,160→ 92,738 total - Award
Stock Option (Right to Buy)
2022-03-15+112,500→ 112,500 totalExercise: $1.11Exp: 2032-03-15→ Common Stock (112,500 underlying)
Footnotes (3)
- [F1]Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
- [F2]Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
- [F3]The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.